Author

Abhijit Ramachandran

Observed name: A. Ramachandran

Observed institutions: The University of Texas MD Anderson Cancer Center, Oregon Health & Science University, The University of Texas at Arlington, Portland VA Medical Center, Arog Pharmaceuticals (United States), OHSU Knight Cancer Institute, The University of Texas Southwestern Medical Center, KU Leuven

OpenAlex ID: A5048425494

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

2013 · Allison Galanis, Hayley Ma, et al. · Blood · 260

Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors

2012 · Michael C. Heinrich, Diana Griffith, et al. · Clinical Cancer Research · 224

Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

2013 · Eric I. Zimmerman, David C. Turner, et al. · Blood · 184

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

2014 · Jasleen K. Randhawa, Hagop M. Kantarjian, et al. · Blood · 122

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

2016 · Jorge E. Cortes, Hagop M. Kantarjian, et al. · Journal of Clinical Oncology · 101

Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1

2015 · Yujiro Hayashi, Michael R. Bardsley, et al. · Gastroenterology · 74

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)

2017 · Madhura Joglekar-Javadekar, Steven Van Laere, et al. · Neoplasia · 71

PDF

Reversal of Acquired Drug Resistance in FLT3 -Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

2014 · Weiguo Zhang, Chen Gao, et al. · Clinical Cancer Research · 64

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

2014 · Carolyn M Cheney, Deborah M Stephens, et al. · mAbs · 41

PDF

Coarse-Grained Molecular Dynamics Simulation of DNA Translocation in Chemically Modified Nanopores

2011 · Abhijit Ramachandran, Qingjiang Guo, et al. · The Journal of Physical Chemistry B · 28

Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).

2014 · Robert Collins, Hagop M. Kantarjian, et al. · Journal of Clinical Oncology · 25

Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.

2016 · Margaret von Mehren, Eric Daniel Tetzlaff, et al. · Journal of Clinical Oncology · 22

Characterization of DNA-Nanopore Interactions by Molecular Dynamics

2009 · Abhijit Ramachandran, Yaling Liu, et al. · American Journal of Biomedical Sciences · 22

PDF

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

2015 · Robert Collins, Hagop M. Kantarjian, et al. · Blood · 9

First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG).

2014 · Cynthia Wetmore, Alberto Broniscer, et al. · Journal of Clinical Oncology · 8

The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors.

2011 · M. C. Heinrich, D. Griffith, et al. · Journal of Clinical Oncology · 8

Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography–electrospray ionization-tandem mass spectrometry (LC–ESI-MS/MS)

2013 · Michael S. Roberts, David C. Turner, et al. · Journal of Chromatography B · 7

Abstract 3660: Crenolanib: A next generation FLT3 inhibitor

2012 · Allison Galanis, Trivikram Rajkhowa, et al. · Cancer Research · 7

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

2015 · Haijiao Zhang, Kevin Matthew Watanabe-Smith, et al. · Blood · 6

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

2015 · John Carl Panetta, Sharyn D Baker, et al. · Blood · 6

Correlation of PET/CT and CT RECIST response in GIST patients with PDGFRA D842V gene mutations treated with crenolanib.

2014 · Jennifer Madeline Matro, Jian Qin Yu, et al. · Journal of Clinical Oncology · 5

Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations

2012 · Allison Galanis, Trivikram Rajkhowa, et al. · Blood · 5

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

2014 · Marcus M Schittenhelm, Figen Akmut, et al. · Blood · 4

Combination of Crenolanib with Sorafenib Produces Synergistic Pro-Apoptotic Effects in FLT3-ITD-Inhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations

2012 · Chen Gao, Weiguo Zhang, et al. · Blood · 2

Abstract 3683: Crenolanib, a novel Type I, mutant-specific inhibitor of Class III receptor tyrosine kinases, preferentially binds to phosphorylated kinases

2012 · Chaitanya Muralidhara, Abhijit Ramachandran, et al. · Cancer Research · 2

Works count: 42

Citation count: 1,310

H-index: 13

I10-index: 13